LNCaP C4-2B Xenograft Model Service for Prostate Cancer

The LNCaP C4-2B cell line provides a highly specialized in vivo platform for investigating metastatic, castration-resistant prostate cancer (mCRPC) with a predilection for bone metastasis. As a premier pre-clinical contract research organization, Alfa Cytology delivers an integrated, high-precision LNCaP C4-2B Xenograft Model Service, meticulously optimized to provide reproducible, audit-ready data packages that accelerate your prostate cancer drug discovery and development pipeline.

Overview of LNCaP C4-2B Xenograft Model for Prostate Cancer

The LNCaP C4-2B xenograft model is an advanced in vivo translational system widely utilized in oncology research for the study of metastatic prostate cancer. Derived from the parental LNCaP cell line through serial passage in castrated male mice, the C4-2B subline exhibits unique biological properties, including the ability to grow in androgen-depleted environments and a distinct capability to colonize bone tissue.

Biologically, the C4-2B model is characterized by its constitutive expression of functional androgen receptors (AR) and prostate-specific antigen (PSA), which allows researchers to investigate AR-driven disease progression even in the absence of circulating androgens. This model closely mimics the clinical progression of human mCRPC, making it an essential system for studying the mechanisms of treatment resistance and evaluating the therapeutic efficacy of novel compounds targeting metastatic dissemination, particularly in the bone microenvironment. Consequently, the C4-2B model is extensively deployed in pre-clinical screening programs to assess the potency of next-generation AR inhibitors, osteoclast-targeting agents, and combination therapies in a physiologically relevant in vivo setting.

Fig 1. A cell line-based model for the progression of prostate cancer. (San Martin R, et al., 2022)

Cell Line Information: LNCaP C4-2B

The LNCaP C4-2B cell line is a subline of the LNCaP lineage, specifically isolated for its metastatic affinity and androgen-independent growth characteristics. These cells are essential for high-fidelity models of advanced prostate cancer progression in vitro and in vivo.

Our Services

Workflow of LNCaP C4-2B Xenograft Model Construction

• Cell Culture & Quality Control: Human LNCaP C4-2B cells are expanded in vitro using certified nutrient media under optimized physiological conditions. STR authentication and mycoplasma screening are performed prior to inoculation to ensure absolute genetic integrity and purity.
• Host Selection & Preparation: Immunodeficient rodent models are utilized for tumor engraftment, with all animals maintained in a controlled, pathogen-free environment to ensure physiological stability and consistency throughout the study.
• Precision Inoculation: A calibrated suspension of high-viability LNCaP C4-2B cells is prepared, often supplemented with an extracellular matrix (e.g., Matrigel) to optimize take rates. Cells are inoculated in vivo via subcutaneous or orthotopic injection to facilitate the development of a measurable solid tumor or metastatic lesion.
• Longitudinal Monitoring: Tumor dimensions are measured systematically using digital calipers or imaging modalities to monitor progression. Animal health, activity, and body weight are recorded periodically to document systemic tolerance and clinical status.
• Randomization & Treatment: Once solid tumors reach a predefined, statistically significant volume, animals are randomized into experimental cohorts to ensure baseline parity before the initiation of customized therapeutic dosing regimens.

Fig 2. LNCaP C4-2B Xenograft Model Construction Workflow

Case Study - LNCaP C4-2B Xenograft Model Development

A pre-clinical validation study was conducted using the LNCaP C4-2B xenograft model to evaluate the therapeutic efficacy of a novel inhibitor targeting the metastatic progression of prostate cancer. Following the successful inoculation of LNCaP C4-2B cells into immunodeficient mice, the host animals developed firm, rapidly growing tumors. The treatment group demonstrated a clear, statistically significant inhibition of tumor growth compared to the vehicle-treated control group, confirming the model's high sensitivity and predictive reliability for screening novel interventions against advanced prostate cancer.

Why Choose Alfa Cytology?

• Oncology Domain Expertise: Profound experience in managing specialized prostate cancer lineages, providing highly reproducible in vivo translational platforms for complex hormonal-resistance research.
• Rigorous Quality Control: Meticulous cell validation and standardized operating procedures that minimize experimental variability across all project stages.
• Tailored Experimental Design: Highly flexible protocols that adapt to specific animal strain requirements, custom dosing schedules, and unique compound properties.
• High-Resolution Deliverables: Every project concludes with a detailed, audit-ready report providing comprehensive tumor growth metrics and statistical validations.

Contact us

Accelerating your prostate cancer drug pipeline requires a pre-clinical partner with the technical proficiency to execute rigorous in vivo workflows flawlessly. If you are looking to advance your novel compound or require specialized pre-clinical testing using our LNCaP C4-2B platform, please reach out to us today to discuss your project requirements with our expert scientific team.

For research use only. Not intended for any clinical use.